Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Morgan Stanley analyst Terence Flynn reiterates equal weight and $26 PT.
That is good news and also fascinating. To what do you attribute this behavioral change?
I've been interested in the institutional holders of late and curious about whether they might be lightening up their positions this last Quarter. Vanguard has just filed and they actually added about 9000 shares, so that is a postiive sign. The big money must report their positions by June 15, so keep an eye out for more filings. Vanguard holds over 10% of HALO and they are second behind Blackrock who haven't filed yet.
To quote a certain billionaire, "Twitter sucks."
WaPo article on Fatty Liver Disease and NASH
https://wapo.st/420gTxv
Thanks for the links. I was not aware of the hype around ARGX and agree that it might put some wind in HALO's sails.
Howee, can you give a link or three to the press you mentioned in regards to ARGX? I've not come across anything like that. Always good to hear from you, hope you are well.
Thanks,
-Fritz
Good summary, thanks. I would add that, after all that wastefull buyback, they now have less than $100 million cash in the bank and are carrying about $1.5 billion in debt. The good news is it appears that this is a bottom FWIW.
What did you think of the latest call?
My source is my newsfeed from my broker I also cross check with Benzinga, which I find pretty reliable. Tipranks is not a trusted source in my eyes.
JMP reiterates outperform maintains $66 PT
Morgan Stanley reiterates overweight but lowers PT from $66 to $60
Piper Sandler upgrades to overweight and sets PT at $46
This is old news from March. See my post
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171544476
I doubt that any analysit would go on the record just hours before the quarterly report is published.
Your point about interest rates is spot on.
Correction: The March 27th issue of The New Yorker, the article is entitled "The Ozempic Era".
FYI, there is a really informative article on GLP-1 in the March 20, 2023 edition of The New Yorker. If you don't have a subscription, you might be able to access it via your local library.
Good summary but I would remove the word "false" from the first two, since the issue is an ongoing uncertainty.
I would also add a fifth and sixth concern: the advent of a possible hyaluronidase competitor and the glacial pace of new partnerships.
All of these, plus the overall market gyrations, pretty much explain the 50% haircut from the historic highs.
-Fritz
dermal fillers might also be indicated.
"Ozempic Face" could arguably put more wind in the sails of RVNC and competitors.
https://www.forbes.com/sites/ariannajohnson/2023/02/01/ozempic-face-explained-why-it-happens-and-how-to-fix-it/?sh=65eeb8bd22c3
By the way, it was the last CFO who was apparently the architect of the financial engineering gimicks which have squandereed literally hundreds of millions of dollars on expensive stock buybacks. I'm glad she is gone.
Yes, the efgartigimod delay was noted here; not welcome news but was not greeted with panic either.
Other negative issues are related patent durability and, recently, some glimmers of competition with the rHuph20 enzyme.
Helen's leadership is looking shakier than ever but my feeling is that the BOD is composed of people she has helped select, so no ope of a leadership change, despite the crying need for it.
I do hope and expect that Helen will be grilled on the next CC. It should be interesting.
Feel free to drop in on West Pharma and make a pitch for the buyout. LOL!!
The deal offers no immediate prospects for future earnings for HALO but argenx has an active partnership with Halozyme that is on the cusp of being very significant for both companies. The hope is that, given this success, they will continue that relationship down the road.
Vin, sorry, I was addressing the guy who was criticising your post without giving his reasons for doing so. Apologise for the ambiguity.
Best,
-Fritz
Please explain your thinking.
Finally the GOP now has an alternative to Obamacare.
Needham's Serge Belanger reiterates buy rating and $40 PT
argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
https://ih.advfn.com/stock-market/NASDAQ/argenx-ARGX/stock-news/90773083/argenx-and-genmab-enter-partnership-to-advance-ant
Right, the option activity is nil but I'm keeping a half an eye on the bids. There is some interest, or at least it appeared that way, but no seller stepped up to the plate. We're never going to see anything like the highs of recent times unless there is a breathtaking deal, and that is looking very unlikely. I think mid-40s might be the best we can hope for at the moment, aside from the unknown unknowns. Helen has driven this car into a ditch. The BOD is probably in her pocket, so no relief coming either.
What else are you looking at in regard to other opportunities?
Rumsfeld the proto fascist, like his current full on fascist successors, was a bottomless pit of ignorance and lies.
That being said, given the imperfect state of our grasp of reality, what is your currrent take on HALO's prospects near and mid term?
Hmmm, if the universe of knowable things = infinity,
does that mean that within the observer there can be no increase of knowledge
and all learning must still = n+zero?
For a while today I noticed a decent bid on the June $45 calls, but nobody sold into it. Therein might be a clue as to the timing of an announcement. Just speculating here.
3rd CFO in (approximately) the last 7 years. The middle one was the authoress of the buyback and other financial engineering gimmicks.
Agreed about the dividend. They constantly speak of "returning value to the shareholders" and a look at the chart shows the full nature of their accomplishments.
Nope. They were sellers, not buyers. We shareholders give them lots of freebies, so they're not going to be buying with their own cash.
Berenberg Bank resumes coverage and institutes a $58 PT. I don't know this bank, but that call is an outlier nowadays.
I'm assuming this is Phesgo, FDA approved in 2020. When was the patent application filed?
TAK-881 is basically Hyqvia, but at double the immunoglobulin concentration, i.e., from 10% to 20%.
TAK-881 is mentioned in HALO's partner pipeline:
https://halozyme.com/drug-delivery-technologies/enhanze/